BR112015023404A8 - composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos - Google Patents

composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos Download PDF

Info

Publication number
BR112015023404A8
BR112015023404A8 BR112015023404A BR112015023404A BR112015023404A8 BR 112015023404 A8 BR112015023404 A8 BR 112015023404A8 BR 112015023404 A BR112015023404 A BR 112015023404A BR 112015023404 A BR112015023404 A BR 112015023404A BR 112015023404 A8 BR112015023404 A8 BR 112015023404A8
Authority
BR
Brazil
Prior art keywords
precursors
age
pharmaceutical compositions
end product
advanced glycation
Prior art date
Application number
BR112015023404A
Other languages
English (en)
Other versions
BR112015023404A2 (pt
Inventor
T Papoulis Andrew
Besev Magnus
Dhal Pradeep
J Miller Robert
Randall Holmes-Farley Stephen
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112015023404A2 publication Critical patent/BR112015023404A2/pt
Publication of BR112015023404A8 publication Critical patent/BR112015023404A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

resumo patente de invenção: "sequestrantes de precursores de produto final de glicação avançada (age)". trata-se de sequestrantes de precursores de age que compreendem aminas separadas por 2, 3 ou 4 carbonos. os sequestrantes de precursores de age podem ser usados como agentes farmacêuticos e em composições farmacêuticas. os sequestrantes de precursores de age são úteis, em particular, ligando precursores de age e dicarbonilas alimentares em mamíferos no trato gastrointestinal para o tratamento de indisposições como neuropatia diabética, doença renal crônica, aterosclerose, derrame, catarata e doença de alzheimer.
BR112015023404A 2013-03-15 2014-03-12 composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos BR112015023404A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (2)

Publication Number Publication Date
BR112015023404A2 BR112015023404A2 (pt) 2017-07-18
BR112015023404A8 true BR112015023404A8 (pt) 2019-12-03

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023404A BR112015023404A8 (pt) 2013-03-15 2014-03-12 composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos

Country Status (24)

Country Link
US (2) US20160024233A1 (pt)
EP (1) EP2968403A1 (pt)
JP (4) JP2016512830A (pt)
KR (1) KR20150130492A (pt)
CN (1) CN105188718A (pt)
AR (1) AR095593A1 (pt)
AU (2) AU2014235500A1 (pt)
BR (1) BR112015023404A8 (pt)
CA (1) CA2906501A1 (pt)
CL (1) CL2015002624A1 (pt)
CR (1) CR20150545A (pt)
DO (1) DOP2015000221A (pt)
EA (1) EA201591733A1 (pt)
HK (1) HK1220607A1 (pt)
IL (1) IL241406A0 (pt)
MA (1) MA38487A1 (pt)
MX (1) MX2015012843A (pt)
PE (1) PE20151766A1 (pt)
PH (1) PH12015502019A1 (pt)
SG (2) SG11201506413PA (pt)
TN (1) TN2015000390A1 (pt)
TW (1) TW201521744A (pt)
UY (1) UY35441A (pt)
WO (1) WO2014150873A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
WO2019046506A1 (en) * 2017-08-31 2019-03-07 Cytosorbents Corporation REDUCTION OF FINAL PRODUCTS OF ADVANCED GLYCATION FROM BODILY FLUIDS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
NZ528831A (en) * 2001-04-18 2005-07-29 Genzyme Corp Method for lowering serum glucose
WO2005032563A1 (en) * 2003-09-02 2005-04-14 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
WO2005079463A2 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
ES2549513T3 (es) * 2010-02-24 2015-10-28 Relypsa, Inc. Polivinilamina, polialilamina y polietilenimina reticuladas para uso como secuestradores de ácidos biliares

Also Published As

Publication number Publication date
JP2020055850A (ja) 2020-04-09
SG11201506413PA (en) 2015-09-29
JP2022037143A (ja) 2022-03-08
CA2906501A1 (en) 2014-09-25
KR20150130492A (ko) 2015-11-23
HK1220607A1 (zh) 2017-05-12
AU2014235500A1 (en) 2015-11-05
AU2019201259A1 (en) 2019-03-14
MA38487A1 (fr) 2017-12-29
TN2015000390A1 (en) 2017-01-03
CL2015002624A1 (es) 2016-03-11
AR095593A1 (es) 2015-10-28
CR20150545A (es) 2015-12-01
PH12015502019A1 (en) 2016-01-11
PE20151766A1 (es) 2015-12-11
WO2014150873A1 (en) 2014-09-25
IL241406A0 (en) 2015-11-30
JP2018135365A (ja) 2018-08-30
DOP2015000221A (es) 2015-12-15
MX2015012843A (es) 2016-08-08
UY35441A (es) 2014-10-31
EA201591733A1 (ru) 2016-01-29
JP2016512830A (ja) 2016-05-09
BR112015023404A2 (pt) 2017-07-18
SG10201707590XA (en) 2017-11-29
US20160024233A1 (en) 2016-01-28
EP2968403A1 (en) 2016-01-20
CN105188718A (zh) 2015-12-23
US20180265613A1 (en) 2018-09-20
TW201521744A (zh) 2015-06-16

Similar Documents

Publication Publication Date Title
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201890204A1 (ru) Антибактериальные соединения
BR112015014372A2 (pt) inibidores de autotaxina
BR112015026830A8 (pt) composto, composição farmacêutica, combinação, produto, uso de um composto, e, método para profilaxia ou tratamento de um estado de doença ou condição
BR112014029762A2 (pt) composição contendo n-metil-n-acilglucamina
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112015008447A2 (pt) métodos para tratar câncer
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PH12015502275B1 (en) Therapuetic uses of empagliflozin
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
MX340985B (es) Compuestos de n-heteroarilo.
BR112016007536A8 (pt) compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
RS53457B (en) COMPOSITION AND ITS APPLICATION IN THE TREATMENT OF ANAL RAGAD
BR112015023404A8 (pt) composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos
BR112013028698A2 (pt) compostos para uso no tratamento de infecções retrovirais em felinos
EA201501177A1 (ru) Фармацевтические композиции
BR112015019084A2 (pt) métodos para aumentar o rendimento das culturas
EA201590782A1 (ru) Оксирановые амины

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements